Dispositions of Enrofloxacin and Its Major Metabolite Ciprofloxacin in Thai Swamp Buffaloes

Overview

Journal J Vet Med Sci

Specialty Veterinary Medicine

Date 2015 Nov 25

PMID 26596287

Citations 5

Authors

Nitwarat Ruennarong

Kannika Wongpanit

Chainarong Sakulthaew

Mario Giorgi

Susumu Kumagai

Amnart Poapolathep

Saranya Poapolathep

Affiliations

Soon will be listed here.

Abstract

Given the limited information available in this species, the aim of this study was to investigate the pharmacokinetic characteristics of enrofloxacin (ER) and its major metabolite ciprofloxacin (CP) in buffaloes, Bubalus bubalis. ER was administered intravenously (i.v.) or subcutaneously (s.c.) to buffaloes at doses of 5.0 and 7.5 mg/kg BW, and plasma, urine and fecal samples were collected until 48 hr post-administration. The concentrations of ER and CP in the plasma, urine and feces were analyzed using high-performance liquid chromatography equipped with a fluorescence detector. The plasma concentrations of ER and CP could be determined up to 24 hr and 32 hr after i.v. and s.c. administrations at doses of 5.0 and 7.5 mg/kg BW, respectively. CP concentrations were always lower than those of parental drug. The s.c. bioavailability of ER was 52.36 ± 4.24% and 72.12 ± 5.39% at doses of 5.0 and 7.5 mg/kg BW, respectively. Both ER and CP were detectable in urine and feces up to 24 hr. ER and CP were mainly excreted via the urine. Based on the pharmacokinetic data and PK-PD indices, s.c. administration of ER at doses of 5.0 and 7.5 mg/kg BW might be appropriate for the treatment of susceptible bacterial diseases in Thai swamp buffaloes.

Citing Articles

Enrofloxacin and Sulfamethoxazole Sorption on Carbonized Leonardite: Kinetics, Isotherms, Influential Effects, and Antibacterial Activity toward ATCC 25923.

Chokejaroenrat C, Sakulthaew C, Satchasataporn K, Snow D, Ali T, Assiri M Antibiotics (Basel). 2022; 11(9).

PMID: 36140040 PMC: 9495318. DOI: 10.3390/antibiotics11091261.

Pharmacokinetic Behavior and Pharmacokinetic/Pharmacodynamic Integration of Danofloxacin Following Single or Co-Administration with Meloxicam in Healthy Lambs and Lambs with Respiratory Infections.

Ural M, Uney K Antibiotics (Basel). 2021; 10(10).

PMID: 34680771 PMC: 8532679. DOI: 10.3390/antibiotics10101190.

Analysis of fluoroquinolones in dusts from intensive livestock farming and the co-occurrence of fluoroquinolone-resistant Escherichia coli.

Schulz J, Kemper N, Hartung J, Janusch F, Mohring S, Hamscher G Sci Rep. 2019; 9(1):5117.

PMID: 30914675 PMC: 6435704. DOI: 10.1038/s41598-019-41528-z.

Exploitation of enrofloxacin-loaded docosanoic acid solid lipid nanoparticle suspension as oral and intramuscular sustained release formulations for pig.

Tao Y, Yang F, Meng K, Chen D, Yang Y, Zhou K Drug Deliv. 2019; 26(1):273-280.

PMID: 30880494 PMC: 6427631. DOI: 10.1080/10717544.2019.1580798.

Development and Validation of a Reproducible and Label-Free Surface Plasmon Resonance Immunosensor for Enrofloxacin Detection in Animal-Derived Foods.

Pan M, Li S, Wang J, Sheng W, Wang S Sensors (Basel). 2017; 17(9).

PMID: 28867795 PMC: 5621032. DOI: 10.3390/s17091984.

References

Kaartinen L, Salonen M, Alli L, Pyorala S . Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cows. J Vet Pharmacol Ther. 1995; 18(5):357-62. DOI: 10.1111/j.1365-2885.1995.tb00604.x. View

Vaccaro E, Giorgi M, Longo V, Mengozzi G, Gervasi P . Inhibition of cytochrome p450 enzymes by enrofloxacin in the sea bass (Dicentrarchus labrax). Aquat Toxicol. 2002; 62(1):27-33. DOI: 10.1016/s0166-445x(02)00064-4. View

Hyatt J, McKinnon P, Zimmer G, Schentag J . The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet. 1995; 28(2):143-60. DOI: 10.2165/00003088-199528020-00005. View

Kaartinen L, Pyorala S, Moilanen M, Raisanen S . Pharmacokinetics of enrofloxacin in newborn and one-week-old calves. J Vet Pharmacol Ther. 1998; 20(6):479-82. DOI: 10.1046/j.1365-2885.1997.00100.x. View

Kung K, Riond J, Wolffram S, Wanner M . Comparison of an HPLC and bioassay method to determine antimicrobial concentrations after intravenous and oral administration of enrofloxacin in four dogs. Res Vet Sci. 1993; 54(2):247-8. DOI: 10.1016/0034-5288(93)90065-n. View

De Lucas J, Solano J, Gonzalez F, Ballesteros C, San Andres M, Martin Von Kauffmann C . Pharmacokinetics of enrofloxacin after multiple subcutaneous and intramuscular administrations in adult ostriches. Br Poult Sci. 2013; 54(3):391-7. DOI: 10.1080/00071668.2013.775402. View

Anadon A, Martinez-Larranaga M, Diaz M, Fernandez-Cruz M, Martinez M, Frejo M . Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. Am J Vet Res. 1999; 60(11):1377-82. View

Mengozzi G, Intorre L, Bertini S, Soldani G . Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and intramuscular administrations in sheep. Am J Vet Res. 1996; 57(7):1040-3. View

McKellar Q, Bruni S, Jones D . Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. J Vet Pharmacol Ther. 2004; 27(6):503-14. DOI: 10.1111/j.1365-2885.2004.00603.x. View

10.

Zhou X, Chen C, Yue L, Sun Y, Ding H, Liu Y . Excretion of enrofloxacin in pigs and its effect on ecological environment. Environ Toxicol Pharmacol. 2011; 26(3):272-7. DOI: 10.1016/j.etap.2008.04.004. View

11.

Rao G, Ramesh S, Ahmad A, Tripathi H, Sharma L, Malik J . Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in goats given enrofloxacin alone and in combination with probenecid. Vet J. 2001; 163(1):85-93. DOI: 10.1053/tvjl.2001.0594. View

12.

Sunderland J, Lovering A, Tobin C, MacGowan A, Roe J, Delsol A . A reverse-phase HPLC assay for the simultaneous determination of enrofloxacin and ciprofloxacin in pig faeces. Int J Antimicrob Agents. 2004; 23(4):390-3. DOI: 10.1016/j.ijantimicag.2003.07.014. View

13.

Prescott J, Yielding K . In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin. Can J Vet Res. 1990; 54(1):195-7. PMC: 1255628. View

14.

Yoshimura H, Ishimaru M, Endoh Y, Kojima A . Antimicrobial susceptibility of Pasteurella multocida isolated from cattle and pigs. J Vet Med B Infect Dis Vet Public Health. 2001; 48(7):555-60. DOI: 10.1046/j.1439-0450.2001.00468.x. View

15.

Drusano G, Johnson D, Rosen M, Standiford H . Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993; 37(3):483-90. PMC: 187696. DOI: 10.1128/AAC.37.3.483. View

16.

Otero J, Mestorino N, Errecalde J . Pharmacokinetics of enrofloxacin after single intravenous administration in sheep. Rev Sci Tech. 2010; 28(3):1129-42. DOI: 10.20506/rst.28.3.1952. View

17.

Messenger K, Papich M, Blikslager A . Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs. J Vet Pharmacol Ther. 2011; 35(5):452-9. DOI: 10.1111/j.1365-2885.2011.01338.x. View

18.

Giguere S, Sweeney R, Belanger M . Pharmacokinetics of enrofloxacin in adult horses and concentration of the drug in serum, body fluids, and endometrial tissues after repeated intragastrically administered doses. Am J Vet Res. 1996; 57(7):1025-30. View

19.

Haines G, Brown M, Gronwall R, Merritt K . Serum concentrations and pharmacokinetics of enrofloxacin after intravenous and intragastric administration to mares. Can J Vet Res. 2000; 64(3):171-7. PMC: 1189609. View

20.

Haritova A, Lashev L, Pashov D . Pharmacokinetics of enrofloxacin in lactating sheep. Res Vet Sci. 2003; 74(3):241-5. DOI: 10.1016/s0034-5288(03)00003-1. View